Table 3.
Genotype frequencies and ORs associated with each gene polymorphism in breast cancer cases and controls
| Gene and SNPs | Genotype | Control n (%) | Case n (%) | P-value# | OR (95% CI) | P –value* |
|---|---|---|---|---|---|---|
| CYP19A1 (rs700519) | GG | 97 (69.3%) | 92 (65.7%) | 0.813 | 1 | – |
| GA | 37 (26.4%) | 41 (29.3%) | 1.17 (0.69–1.98) | 0.564 | ||
| AA | 6 (4.3%) | 7 (5.0%) | 1.23 (0.40–3.80) | 0.719 | ||
| CYP1A1 (rs1048943) | TT | 100 (71.4%) | 80 (57.1%) | 0.007 | 1 | – |
| TC | 31 (22.2%) | 55 (39.3%) | 2.37 (1.27–4.43) | 0.003 | ||
| CC | 9 (6.4%) | 5 (3.6%) | 1.10 (0.30–4.00) | 0.528 | ||
| CYP1A1 (rs4649903) | AA | 68 (48.6%) | 58 (41.4%) | 0.300 | 1 | – |
| AG | 56 (40.0%) | 58 (41.4%) | 1.21 (0.73–2.02) | 0.453 | ||
| GG | 16 (11.4%) | 24 (17.1%) | 1.76 (0.85–3.62) | 0.126 | ||
| CYP1B1 (rs1056827) | CC | 92 (65.7%) | 80 (57.1%) | 0.004 | 1 | – |
| CA | 48 (34.3%) | 50 35.7%) | 1.20 (0.73–1.97) | 0.802 | ||
| AA | 0 (0.0%) | 10 (7.2%) | 6.90 (1.50–31.76) | 0.001 | ||
| CYP1B1 (rs1056836) | GG | 90 (64.3%) | 116 (82.9%) | 0.002 | 1 | – |
| GC | 44 (31.4%) | 21 (15.0%) | 0.37 (0.21–0.67) | 0.001 | ||
| CC | 6 (4.3%) | 3 (2.1%) | 0.39 (0.10–1.59) | 0.189 | ||
| HSD17B1 (rs605059) | GG | 47 (33.6%) | 46 (32.9%) | 0.713 | 1 | – |
| GA | 73 (52.1%) | 69 (49.3%) | 0.97 (0.57–1.63) | 0.896 | ||
| AA | 20 (14.3%) | 25 (17.8%) | 1.28 (0.63–2.61) | 0.502 | ||
| COMT (rs4680) | GG | 91 (65.0%) | 80 (57.1%) | 0.402 | 1 | – |
| GA | 42 (30.0%) | 51 (36.4%) | 1.38 (0.83–2.29) | 0.212 | ||
| AA | 7 (5.0%) | 9 (6.4%) | 1.46 (0.52–4.11) | 0.470 | ||
| SULT1A1 (rs1042028) | CC | 117 (83.6%) | 98 (70.0%) | 0.029 | 1 | – |
| CT | 20 (14.3%) | 37 (26.4%) | 2.21 (1.20–4.05) | 0.010 | ||
| TT | 3 (2.1%) | 5 (3.6%) | 1.99 (0.46–8.54) | 0.354 | ||
| UGT2B7 (rs7439366) | CC | 69 (49.30%) | 64 (45.7%) | 0.824 | 1 | – |
| CT | 60 (42.80%) | 65 (46.4%) | 1.17 (0.72–1.90) | 0.533 | ||
| TT | 11 (7.90%) | 11 (7.90%) | 1.08 (0.44–2.66) | 0.870 | ||
| ZNF365 (rs10822013) | CC | 36 (25.71%) | 43 (30.71%) | 0.640 | 1 | – |
| CT | 75 (53.57%) | 71 (50.71%) | 0.79 (0.46–1.37) | 0.407 | ||
| TT | 29 (20.71%) | 26 (18.57%) | 0.75 (0.38–1.50) | 0.415 | ||
| FGFR2 (rs2981579) | GG | 47 (33.57%) | 40 (28.57%) | 0.418 | 1 | – |
| GA | 70 (50.00%) | 69 (49.29%) | 1.16 (0.68–1.98) | 0.592 | ||
| AA | 23 (16.43%) | 31 (22.14%) | 1.58 (0.80–3.14) | 0.188 | ||
| RAD51B (rs3784099) | GG | 111 (79.29%) | 109 (77.86%) | 0.848 | 1 | – |
| GA | 25 (17.86%) | 28 (20.00%) | 1.14 (0.63–2.08) | 0.668 | ||
| AA | 4 (2.86%) | 3 (2.14%) | 0.76 (0.17–3.49) | 0.728 | ||
| TOX3 (rs3803662) | GG | 15 (10.71%) | 18 (12.86%) | 0.664 | 1 | – |
| GA | 61 (43.57%) | 54 (38.57%) | 0.83 (0.51–1.38) | 0.475 | ||
| AA | 64 (45.71%) | 68 (48.57%) | 1.13 (0.53–2.43) | 0.755 | ||
| MAP3K1 (rs889312) | CC | 42 (30.00%) | 35 (25.00%) | 0.460 | 1 | – |
| CA | 67 (47.86%) | 66 (47.14%) | 1.18 (0.67–2.08) | 0.560 | ||
| AA | 31 (22.14%) | 39 (27.86%) | 1.51 (0.79–2.89) | 0.215 | ||
| HCN1 (rs981782) | CC | 16 (11.43%) | 25 (17.86%) | 0.475 | 1 | – |
| CA | 69 (49.29%) | 63 (45.00%) | 0.92 (0.55–1.53) | 0.737 | ||
| AA | 55 (39.29%) | 52 (37.14%) | 1.45 (0.68–3.08) | 0.336 |
Values are presented as number (%) or OR (95% CI)
OR Odds radio, CI Confidence interval, SNP Single nuclear polymorphism
#Comparison of polymorphic genotype distributions in patients with breast cancer and healthy case-controls
*Comparison of wild-type genotypes with heterozygous genotypes and homozygous variant genotypes respectively